IRIS
CIARDIELLO, Fortunato
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 34.381
NA - Nord America 17.531
AS - Asia 14.309
SA - Sud America 2.377
AF - Africa 168
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 18
Totale 68.815
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 22.162
US - Stati Uniti d'America 17.277
SG - Singapore 5.023
IE - Irlanda 3.520
CN - Cina 2.992
HK - Hong Kong 2.475
BR - Brasile 2.025
UA - Ucraina 1.725
IT - Italia 1.628
VN - Vietnam 1.625
GB - Regno Unito 1.594
DE - Germania 1.281
FR - Francia 635
KR - Corea 603
FI - Finlandia 538
SE - Svezia 470
IN - India 428
GR - Grecia 352
TR - Turchia 346
JP - Giappone 246
CA - Canada 134
AR - Argentina 132
NL - Olanda 95
AT - Austria 92
BD - Bangladesh 91
ID - Indonesia 86
PK - Pakistan 78
MX - Messico 77
IQ - Iraq 71
PL - Polonia 70
EC - Ecuador 66
ES - Italia 48
BE - Belgio 47
CO - Colombia 39
ZA - Sudafrica 37
MA - Marocco 33
VE - Venezuela 32
CZ - Repubblica Ceca 30
PY - Paraguay 28
SA - Arabia Saudita 28
CL - Cile 25
AU - Australia 22
JO - Giordania 19
EG - Egitto 17
IL - Israele 17
AE - Emirati Arabi Uniti 16
AZ - Azerbaigian 16
KE - Kenya 16
TH - Thailandia 16
UZ - Uzbekistan 16
CH - Svizzera 15
EU - Europa 15
IR - Iran 15
PH - Filippine 15
DZ - Algeria 14
TN - Tunisia 14
NP - Nepal 13
AL - Albania 12
LT - Lituania 12
MY - Malesia 12
DO - Repubblica Dominicana 11
PE - Perù 11
BO - Bolivia 10
HU - Ungheria 8
KG - Kirghizistan 8
NZ - Nuova Zelanda 8
SN - Senegal 8
TW - Taiwan 8
CR - Costa Rica 7
JM - Giamaica 7
LB - Libano 7
HR - Croazia 6
KZ - Kazakistan 6
UY - Uruguay 6
AO - Angola 5
CG - Congo 5
HN - Honduras 5
RO - Romania 5
TT - Trinidad e Tobago 5
BH - Bahrain 4
BY - Bielorussia 4
ET - Etiopia 4
LV - Lettonia 4
MK - Macedonia 4
OM - Oman 4
RS - Serbia 4
BG - Bulgaria 3
GY - Guiana 3
KW - Kuwait 3
MM - Myanmar 3
PT - Portogallo 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
BB - Barbados 2
CI - Costa d'Avorio 2
EE - Estonia 2
GA - Gabon 2
GI - Gibilterra 2
GT - Guatemala 2
LK - Sri Lanka 2
Totale 68.774
Salva come PNG Salva come JPEG
Città #
Moscow 7.948
Dublin 3.502
Jacksonville 2.639
Hong Kong 2.443
Singapore 1.998
Santa Clara 1.861
San Jose 1.797
Chandler 1.692
Ashburn 722
Wilmington 694
Seoul 576
Chicago 559
Princeton 557
Ho Chi Minh City 547
Medford 493
Hefei 451
Hanoi 373
New York 357
Falls Church 334
Beijing 318
Boardman 311
San Mateo 292
Bengaluru 289
Dallas 269
Naples 267
Roxbury 257
Ann Arbor 250
Bremen 231
Munich 211
The Dalles 209
Caserta 184
Los Angeles 183
São Paulo 172
Woodbridge 161
Cambridge 124
Des Moines 118
Nanjing 97
Da Nang 92
Nuremberg 85
Haiphong 71
Houston 69
Jinan 64
Rio de Janeiro 64
Council Bluffs 59
Elora 59
Turku 57
Amsterdam 52
Mountain View 52
Belo Horizonte 51
Napoli 50
Vienna 50
Shanghai 49
Orem 46
Dong Ket 42
Helsinki 42
Milan 42
Norwalk 42
Brussels 40
Tokyo 40
Düsseldorf 39
Tianjin 39
Nanchang 36
Warsaw 36
Guangzhou 35
Aversa 34
Brasília 34
Curitiba 34
Frankfurt am Main 34
Lappeenranta 34
Atlanta 33
Hải Dương 33
Chennai 31
Falkenstein 31
Rome 31
London 30
Brooklyn 28
Campinas 27
Shenyang 27
Changsha 26
Columbus 26
Kraków 26
Manchester 26
Quito 26
Jakarta 25
Ninh Bình 25
Biên Hòa 24
Guarulhos 24
Istanbul 24
Thái Bình 24
Brno 23
Goiânia 23
Hillsboro 23
Auburn Hills 22
Porto Alegre 22
Ribeirão Preto 22
Salvador 22
Venice 22
Guayaquil 21
San Francisco 21
Redwood City 20
Totale 35.847
Salva come PNG Salva come JPEG
Nome #
Epigenetic mechanisms underlying prostate cancer radioresistance 1.424
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 244
Beyond N staging in colorectal cancer: Current approaches and future perspectives 219
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 214
ONCOLOGIA MEDICA 206
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis 205
A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. 204
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 201
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. 201
AXL is an oncotarget in human colorectal cancer 194
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? 192
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 190
A trimodality, four-step treatment including chemotherapy, pleurectomy/decortication and radiotherapy in early-stage malignant pleural mesothelioma: A single-institution retrospective case series study 184
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 182
Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis 181
Adjuvant chemoradiotherapy in patients with stage III-IV radically resected gastric cancer: a pilot study 181
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 181
Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma—a pilot study. Curr Oncol 21, 3, june 2014 125-133 179
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 178
A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells 177
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients 177
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 177
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 177
Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells 175
CBX2 shapes chromatin accessibility promoting AML via p38 MAPK signaling pathway 174
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: A propensity score-matched analysis 173
A possible connective tissue primary lymphoepithelioma-like carcinoma (LELC). 172
Immunotherapy for head and neck cancer: Present and future 171
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 170
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 170
Chronic inflammation and oxidative stress in human carcinogenesis 169
Clinical management of advanced gastric cancer: Role of new molecular drugs. 166
A preliminary study for quantitative assessment with HFUS (High-frequency ultrasound) of nodular skin melanoma breslow thickness in adults before surgery: Interdisciplinary team experience 166
A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics 165
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 164
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 163
Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study) 162
Intraoperative ultrasound: "Alternative eye" in lymph nodal dissection in non-small cell lung cancer 161
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 161
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 159
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 159
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 158
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 158
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 158
Modified blade: an interventional option in rigid bronchoscopy for non-resectable benign tracheal stenosis 157
Intraoperative ventilatory leak: Real-time guidance for management of air leak in lung cancer patients undergoing VATS lobectomy 157
Prediction of preoperative intrathoracic adhesions for ipsilateral reoperations: sliding lung sign 157
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 157
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 157
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 157
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 156
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 156
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 154
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 154
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 154
Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics 153
Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials 153
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 150
CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial 150
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer 150
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. 150
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer 150
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 150
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 149
Conversion chemotherapy followed by epatic resection in colorectal cancer with initially unresectable liver-limited metastases 149
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 149
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 149
Clinical management of metastatic colorectal cancer in the era of precision medicine 149
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 148
AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma 148
Treatment of gastric cancer. 147
Clinical activity of regorafenib in elderly patients with recurrent glioblastoma 146
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial 146
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 146
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 146
1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. 145
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy 145
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 145
Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota 145
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 145
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 144
Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis 144
Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer 144
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials 144
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 144
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 143
8-chloro-cAMP enhances the growth inhibitory effect of cytotoxic drugs in humancolon cancer cells 142
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 142
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 142
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 141
Intraoperative lung ultrasound improves subcentimetric pulmonary nodule localization during VATS: Results of a retrospective analysis 140
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors 140
8-chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo 140
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor 140
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 139
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 139
Antiangiogenic drugs in non small cell lung cancer treatment 139
Addition of metformin to anti-PD-1/PD-L1 drugs activates anti- tumor immune response in peripheral immune cells of NSCLC patients 138
Identification of Tissue miRNA Signatures for Pancreatic Ductal Adenocarcinoma 138
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 138
Totale 17.382
Salva come PNG Salva come JPEG
Categoria #
all - tutte 231.736
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 231.736
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.090 0 0 0 0 0 0 0 0 0 504 426 160
2021/20224.183 400 171 288 158 1.304 73 83 114 159 165 300 968
2022/20237.055 796 176 392 603 674 567 31 366 3.135 44 136 135
2023/20242.895 245 89 130 249 998 337 61 61 48 27 199 451
2024/20258.974 97 169 120 305 1.245 1.098 894 846 1.204 1.773 650 573
2025/202636.718 1.423 1.752 2.045 1.998 2.916 20.660 2.002 1.721 1.460 741 0 0
Totale 69.857